This study evaluated 103 high-risk chronic heart failure patients after acute decompensation who were randomized to either NT-proBNP guided therapy or standard therapy. Biomarkers including NT-proBNP, sST2, copeptin, galectin-3, and troponin T were measured at baseline, 3 months, and 6 months. NT-proBNP guided therapy aimed to reduce NT-proBNP levels by at least 50% from baseline. NT-proBNP guided therapy resulted in greater reductions in biomarkers and lower rates of cardiovascular events compared to standard therapy over 10 months of follow-up. Biomarker changes correlated with improvements in left ventricular function and filling pressures, suggesting guided
Similar to Biomarkers activity and the effect of nt pro bnp guided therapy in high risk patients with chronic heart failure after acute decompensation (20)
3. Purpose of the study
to evaluate the change of the biomarkers
concentration in the group of heart failure (HF)
therapy guided by NT-proBNP versus standard
treatment of CHF patients at high risk after acute
decompensation